Neviah Genomics

Company Overview

Snapshot

Founded in November 2012, Neviah Genomics operates with 11–50 employees. The company secured its A Round funding in August 2012, with M Ventures participating as an investor. In January 2015, Neviah Genomics achieved a key development milestone for its PropheTox™ bioassay, designed for the early prediction of drug-induced liver toxicity.

Business overview

Neviah Genomics specializes in developing screening services for early detection of drug-induced toxicity. Its core product, PropheTox, is a drug toxicity screening service that utilizes mathematical analysis of cell behavior after exposure to various compounds. The technology employs an iterative process involving toxicity assays, machine learning, and biological knowledge to predict low-dose, chronic toxic effects. Neviah Genomics serves the pharmaceutical industry, laboratories, and patients within the Health Tech & Life Sciences sector, focusing on diagnostics and screening.

Strategic signal

In January 2015, Neviah Genomics announced a significant development milestone for its PropheTox™ bioassay, alongside securing additional financing. This achievement signals the company's progress in advancing its technology for early prediction of drug-induced liver toxicity, which is crucial for pharmaceutical companies in drug development and safety assessment. For investors, this indicates validation of their research and development efforts and potential for future commercialization in the health tech and life sciences market.

Company Intelligence Q&A

What is Neviah Genomics' primary product?

Neviah Genomics' primary product is PropheTox, a drug toxicity screening service designed for the early detection of drug-induced toxicity.

When was Neviah Genomics founded?

Neviah Genomics was founded in November 2012.

What was a key development milestone for Neviah Genomics in early 2015?

In January 2015, Neviah Genomics achieved a key development milestone for its PropheTox™ bioassay, which is designed for the early prediction of drug-induced liver toxicity.

Which investor participated in Neviah Genomics' A Round funding?

In August 2012, M Ventures participated as an investor in Neviah Genomics' A Round funding.

What technology underpins the PropheTox service?

The PropheTox service is based on the mathematical analysis of cell behavior following exposure to compounds, utilizing an iterative process involving toxicity assays, machine learning, and prior biological knowledge.